Link Pharma Chem (524748)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Revenue growth of 26.03% shows expanding topline in a commodity chemicals business.
• Profit growth of 110.45% indicates a swing toward better profitability, albeit from a very low base.
• Piotroski F-Score of 6/9 suggests the financial position is not deteriorating.
• Book value of ₹29.04 provides a measurable asset floor; P/B of 1.50 is not extremely stretched.

Concerns

• ROE of 0.99% and ROCE of -3.00% mean returns are far below acceptable capital efficiency.
• Trailing P/E of 86.57 with latest quarter net profit of ₹0 Cr leaves almost no current earnings support.
• Zero dividend yield means minority shareholders receive no income while waiting for a turnaround.
• Promoter holding and debt/equity are not available, so there is no clear visibility on insider skin-in-the-game or leverage.

AI Analysis

At first glance, the 26.03% sales growth and 110.45% profit growth at Link Pharma Chem catch my eye. But Graham taught me to look beneath the surface. This is a ₹19 crore commodity chemicals company with a trailing P/E of 86.57. That implies an earnings yield of barely 1.15%, and the latest quarter shows net profit of roughly zero rupees. A business earning almost nothing today is being priced for extraordinary tomorrows. I also see ROE of 0.99% and ROCE of minus 3.00%. Equity holders earn less than one percent, and the company is not earning its cost of capital. That is not the hallmark of a franchise; it looks like a cyclical commodity operation without pricing power. Book value is ₹29.04, so at ₹43.54 I am paying a 50% premium to stated assets for a sub-1% return. No dividend means I am not paid to wait. The Piotroski score of 6 offers some comfort that the financial position is not deteriorating, and the stock is at its 52-week high, so the market is noticing the topline progress. But the profit jump comes from a tiny base; one quarter with ₹7 crore sales and zero net profit shows how little real earnings exist. Even the PEG of 1.27 leans on that growth burst, not on visible current profitability. I would also like to assess promoter holding and debt, but those data are unavailable. Mr. Market is optimistic; I need margin of safety. With negative ROCE, 86 times earnings, and no dividend, this does not meet my standards. I will keep it on my watchlist and wait for either a much lower price or several quarters of consistently improving returns on capital.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer